Addex Therapeutics (ADXN) News Today → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Free ADXN Stock Alerts $15.41 -0.14 (-0.90%) (As of 04/25/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineAddex to Present at the Swiss Biotech Day 2024globenewswire.com - April 19 at 1:00 AMADXN Stock Earnings: Addex Therapeutics Reported Results for Q4 2023investorplace.com - April 18 at 7:02 AMAddex Therapeutics GAAP EPS of -CHF 0.14, revenue of CHF 1.65Mseekingalpha.com - April 18 at 6:36 AMAddex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Updateglobenewswire.com - April 18 at 1:00 AMAddex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024globenewswire.com - April 11 at 1:00 AMNeurosterix launches with $63M to Advance Allosteric Modulator Therapeutics for Neurological Disordersfinanznachrichten.de - April 3 at 3:30 AMAddex Announces Launch Of Neurosterix In Partnership With Perceptive - Quick Factsmarkets.businessinsider.com - April 3 at 3:30 AMAddex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disordersglobenewswire.com - April 3 at 1:00 AMAddex to Present at the Bio-Europe Spring 2024 Conferenceglobenewswire.com - March 14 at 2:00 AMAddex Therapeutics Stock (NASDAQ:ADXN), Short Interest Reportbenzinga.com - February 22 at 10:12 AMAddex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.finance.yahoo.com - January 31 at 3:37 AMAddex to Present at the Swiss Equities Baader Conferencefinance.yahoo.com - January 9 at 10:15 AMAddex to Present at Biotech Showcase™ 2024finance.yahoo.com - January 5 at 5:19 AMAddex Therapeutics Ltdthestreet.com - December 23 at 9:05 AMAddex Therapeutics: Addex Shareholders Approve All Resolutions at Extraordinary General Meetingfinanznachrichten.de - December 20 at 8:19 AMAddex Shareholders Approve All Resolutions at Extraordinary General Meetingfinance.yahoo.com - December 20 at 1:12 AMAddex Creates Treasury Sharesfinance.yahoo.com - December 14 at 2:13 AMmarketbeat.com - December 5 at 3:59 PMAddex Therapeutics GAAP EPS of -CHF0.03, income of CHF0.33Mmsn.com - November 29 at 7:51 AMAddex Therapeutics Posts Narrower Loss In Q3 - Quick Factsmarkets.businessinsider.com - November 29 at 7:51 AMAddex Reports Q3 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - November 29 at 7:51 AMAddex Convenes Extraordinary General Meetingfinance.yahoo.com - November 28 at 3:01 AMAddex Therapeutics to Release Third Quarter 2023 Financial Results and Host Conference Call on November 29, 2023finance.yahoo.com - November 23 at 9:24 AMAddex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patientsfinance.yahoo.com - November 14 at 8:37 AMAddex Announces Participation in the Bio-Europe 2023 Conferencefinance.yahoo.com - November 2 at 10:28 AMAddex Therapeutics: Addex Completes ADS Ratio Changefinanznachrichten.de - October 21 at 2:34 PMAddex Completes ADS Ratio Changefinance.yahoo.com - October 20 at 1:42 AMAddex To Implement ADS Ratio Changemarkets.businessinsider.com - October 6 at 7:15 PMAddex Therapeutics focused on securing new partnerships to fund promising treatmentsfinance.yahoo.com - October 5 at 2:15 PMH.C. Wainwright Reaffirms Their Hold Rating on Addex Therapeutics (ADXN)markets.businessinsider.com - September 25 at 11:16 AMAddex Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conferencefinance.yahoo.com - September 6 at 2:57 AMAddex ADX71149 Phase 2 Epilepsy Study Expected to Readout Data in Q2 2024benzinga.com - September 5 at 2:55 AMAddex ADX71149 Phase 2 Epilepsy Study Expected to Readout Data in Q2 2024finance.yahoo.com - September 5 at 2:55 AMAddex’s Dipraglurant Development in Post-Stroke Recovery Supported by Data Published in Brainfinance.yahoo.com - September 4 at 1:35 AMAddex Therapeutics: Addex Reports 2023 Half Year and Second Quarter Financial Results and Provides Corporate Updatefinanznachrichten.de - August 10 at 9:45 AMAddex Reports 2023 Half Year and Second Quarter Financial Results and Provides Corporate Updatefinance.yahoo.com - August 10 at 9:45 AMWhat Wall Street expects from Addex Therapeutics's earningsmarkets.businessinsider.com - August 9 at 7:09 PMAddex Therapeutics to Release Half-Year 2023 Financial Results and Host Conference Call on August 10, 2023finance.yahoo.com - August 4 at 2:00 AMAddex GABAB Positive Allosteric Modulator Program to Receive Additional CHF2.7 Million from Indivior in Extended Substance Use Disorder Research Collaborationfinance.yahoo.com - August 3 at 7:47 AMAddex Therapeutics: Addex Shareholders Approve All Resolutions at Annual General Meetingfinanznachrichten.de - June 1 at 9:52 AMEarnings Scheduled For May 11, 2023msn.com - May 11 at 4:42 PMAddex Reports Q1 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - May 11 at 4:44 AMAddex Announces ADX71149 Phase 2 Epilepsy Clinical Study’s Independent Interim Review Committee Recommends Continuing Studyfinance.yahoo.com - May 10 at 3:40 AMAddex Convenes Annual General Meeting 2023finance.yahoo.com - May 5 at 3:58 AMAddex Therapeutics to Release Q1 2023 Financial Results and Host Conference Call on May 11, 2023finance.yahoo.com - May 4 at 2:53 AMAddex Therapeutics: Addex Publishes Dipraglurant Data Showing In Vivo Efficacy on Motor and Non-Motor Symptoms of Parkinson's Diseasefinanznachrichten.de - April 4 at 8:41 AMAddex Publishes Dipraglurant Data Showing In Vivo Efficacy on Motor and Non-Motor Symptoms of Parkinson’s Diseasefinance.yahoo.com - April 4 at 1:21 AMAddex Raises $5.0 Million in Equity Financingfinance.yahoo.com - April 3 at 5:18 AMAddex Reports Full Year 2022 Financial Results and Provides Corporate Updatefinance.yahoo.com - March 30 at 1:35 AMAddex Therapeutics to Release Full-Year 2022 Financial Results and Host Conference Call on March 30, 2023finance.yahoo.com - March 28 at 8:59 AM Get Addex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADXN and its competitors with MarketBeat's FREE daily newsletter. Email Address A new way to collect income from stocks (Ad)Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera. ADXN Media Mentions By Week ADXN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ADXN News Sentiment▼0.390.41▲Average Medical News Sentiment ADXN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ADXN Articles This Week▼20▲ADXN Articles Average Week Get Addex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADXN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Aptorum Group News BioVie News RenovoRx News Vincerx Pharma News Alaunos Therapeutics News Galecto News Onconova Therapeutics News Flora Growth News NeuroSense Therapeutics News Indaptus Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ADXN) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe AI stock to buy right nowStockEarnings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Addex Therapeutics Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
